3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Genitourinary
2
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
26
Lung Neoplasms
23
Neoplasms
7
Small Cell Lung Carcinoma
5
Neoplasm Metastasis
4
Mesothelioma
4
Breast Neoplasms
4
Vomiting
3
Nausea
3
Triple Negative Breast Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Kidney Neoplasms
2
Head and Neck Neoplasms
2
Brain Neoplasms
2
Stomach Neoplasms
1
Radiation Pneumonitis
1
Postoperative Complications
1
Pain, Postoperative
1
Nasopharyngeal Neoplasms
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Melanoma
1
Malnutrition
1
Lymphoma
1
Lung Diseases, Interstitial
1
Liver Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Interventions
pembrolizumab
44
Carboplatin
17
Pemetrexed
14
Paclitaxel
13
Cisplatin
13
lenvatinib
5
Etoposide
5
Docetaxel
5
epacadostat
4
Gemcitabine
4
Albumin-Bound Paclitaxel
4
durvalumab
3
Nivolumab
3
130-nm albumin-bound paclitaxel
3
spartalizumab
2
olaparib
2
Saline Solution
2
Immune Checkpoint Inhibitors
2
Dexamethasone
2
Acetaminophen
2
sacituzumab govitecan
1
ribociclib
1
patritumab deruxtecan
1
osimertinib
1
etoposide phosphate
1
efineptakin alfa
1
cemiplimab
1
camrelizumab
1
avelumab
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Dexamethasone
×
Thoracic
×
Clear all
NCT06788912
2026-05-26
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2
Recruiting
60 enrolled
NCT03950674
2024-06-10
MK-3475-189
Merck Sharp & Dohme LLC
Phase 3
Completed
40 enrolled
20 charts